{
  "id": "5880e417713cbdfd3d000001",
  "type": "factoid",
  "question": "Which disease is treated with ZMapp?",
  "ideal_answer": "ZMapp is a combination of antibodies for treatment of Ebola virus disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25694097",
    "http://www.ncbi.nlm.nih.gov/pubmed/25171469",
    "http://www.ncbi.nlm.nih.gov/pubmed/29179602",
    "http://www.ncbi.nlm.nih.gov/pubmed/29688496",
    "http://www.ncbi.nlm.nih.gov/pubmed/27274814",
    "http://www.ncbi.nlm.nih.gov/pubmed/26311869",
    "http://www.ncbi.nlm.nih.gov/pubmed/25404321",
    "http://www.ncbi.nlm.nih.gov/pubmed/26962157",
    "http://www.ncbi.nlm.nih.gov/pubmed/27279622",
    "http://www.ncbi.nlm.nih.gov/pubmed/29736037",
    "http://www.ncbi.nlm.nih.gov/pubmed/27067649",
    "http://www.ncbi.nlm.nih.gov/pubmed/26798032",
    "http://www.ncbi.nlm.nih.gov/pubmed/26861827",
    "http://www.ncbi.nlm.nih.gov/pubmed/27683818",
    "http://www.ncbi.nlm.nih.gov/pubmed/30053153",
    "http://www.ncbi.nlm.nih.gov/pubmed/25465382",
    "http://www.ncbi.nlm.nih.gov/pubmed/26191408",
    "http://www.ncbi.nlm.nih.gov/pubmed/26946569",
    "http://www.ncbi.nlm.nih.gov/pubmed/25414384",
    "http://www.ncbi.nlm.nih.gov/pubmed/27521366",
    "http://www.ncbi.nlm.nih.gov/pubmed/25760722",
    "http://www.ncbi.nlm.nih.gov/pubmed/28073857",
    "http://www.ncbi.nlm.nih.gov/pubmed/25352204",
    "http://www.ncbi.nlm.nih.gov/pubmed/27637475",
    "http://www.ncbi.nlm.nih.gov/pubmed/25648233",
    "http://www.ncbi.nlm.nih.gov/pubmed/27676206",
    "http://www.ncbi.nlm.nih.gov/pubmed/25260583",
    "http://www.ncbi.nlm.nih.gov/pubmed/27465308",
    "http://www.ncbi.nlm.nih.gov/pubmed/25387576",
    "http://www.ncbi.nlm.nih.gov/pubmed/28357917",
    "http://www.ncbi.nlm.nih.gov/pubmed/25648530",
    "http://www.ncbi.nlm.nih.gov/pubmed/27732819",
    "http://www.ncbi.nlm.nih.gov/pubmed/27959624"
  ],
  "snippets": [
    {
      "text": "Gene Transfer of ZMapp Antibodies Mediated by Recombinant Adeno-Associated Virus Protects Against Ebola Infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29179602",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Vectored delivery of the ZMapp antibody cocktail (c2G4, c4G7, and c13C6) by using recombinant adeno-associated viruses (rAAVs) could be useful for preventive immunization against Ebola virus infections because rAAVs can generate long-term antibody expression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29179602",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ZMapp Reinforces the Airway Mucosal Barrier Against Ebola Virus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688496",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Addition of ZMapp, a cocktail of Ebola-binding immunoglobulin G antibodies, effectively reduced mobility of Ebola pseudovirus in the same mucus secretions. Topical delivery of ZMapp to the mouse airways also facilitated rapid elimination of Ebola pseudovirus. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688496",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several strategies have been developed in the past to treat EBOV infection, including the antibody cocktail ZMapp, which has been shown to be effective in nonhuman primate models of infection 1 and has been used under compassionate-treatment protocols in humans 2 ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29736037",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Antibody therapy has been used to treat a variety of diseases and the success of ZMapp and other monoclonal antibody-based therapies during the 2014-2016 West African Ebola outbreak has shown this countermeasure can be a successful therapy for Ebola hemorrhagic fever. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053153",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Only recently have vaccine or drug regimens for the Ebola virus been developed, including Zmapp and peptides. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27637475",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Numerous therapeutics were explored or developed during the outbreak, including repurposed drugs, nucleoside and nucleotide analogues (BCX4430, brincidofovir, favipiravir, and GS-5734), nucleic acid-based drugs (TKM-Ebola and AVI-7537), and immunotherapeutics (convalescent plasma and ZMapp).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27959624",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The patient was treated with monoclonal antibodies (ZMapp), a buffy coat transfusion from an Ebola survivor, and the broad-spectrum antiviral GS-5734.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28073857",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, during the recent outbreak, monoclonal antibody cocktails such as ZMapp, ZMAb and MB-003 were either tested in a human clinical safety and efficacy trial or provided to some based on compassionate grounds.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28357917",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cocktails of inhibitory monoclonal antibodies (MAbs), such as ZMAb, MB-003, and in particular ZMapp, have demonstrated in animal models some of the most significant therapeutic potential for treating EVD, and in 2014, 15 patients were treated with ZMapp or ZMAb under compassionate-use protocols.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\n\nData from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For example, several patients of the present Ebola virus outbreak in West Africa were treated with ZMapp, a cocktail of three monoclonal antibodies which are expressed in Nicotiana benthamiana.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26191408",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The patient was treated with monoclonal antibodies (ZMapp), a buffy coat transfusion from an Ebola survivor, and the broad-spectrum antiviral GS-5734.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28073857",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Data from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease ( EVD ) .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several patients with Ebola virus disease ( EVD ) managed in the United States have received ZMapp monoclonal antibodies , TKM-Ebola small interfering RNA , brincidofovir , and/or convalescent plasma as investigational therapeutics .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27521366",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nData from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS\nBeginning in March 2015, we conducted a randomized, controlled trial of ZMapp plus the current standard of care as compared with the current standard of care alone in patients with EVD that was diagnosed in West Africa by polymerase-chain-reaction (PCR) assay.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "During the 2014 Ebola outbreak, an experimental drug named ZMapp was administered on an emergency basis to seven patients of which five were recovered.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26946569",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Data from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Data from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26861827",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This includes agents belonging to various therapeutic classes, namely direct antiviral agents (favipiravir and BCX4430), a combination of antibodies (ZMapp), type I interferons, RNA interference-based drugs (TKM-Ebola and AVI-7537), and anticoagulant drugs (rNAPc2). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26861827",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent successes with monoclonal antibody cocktails ZMapp(TM) and MIL77 against Ebola virus (EBOV) infections have reignited interest in antibody-based therapeutics. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067649",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The human-mouse chimeric monoclonal antibody (mAb) cocktail ZMapp, previously shown to be efficacious in EBOV (variant Kikwit) lethally infected nonhuman primates (NHPs) when administration was initiated up to 5 days, was used in some patients during the outbreak. We show that a two-antibody cocktail, MIL77E, is fully protective in NHPs when administered at 50 mg/kg 3 days after challenge with a lethal dose of EBOV variant Makona, the virus responsible for the ongoing 2014-2015 outbreak, whereas a similar formulation of ZMapp protected two of three NHPs. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962157",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The growing promise of plant-made biologics is highlighted by the success story of ZMapp\u2122 as a potentially life-saving drug during the Ebola outbreak of 2014-2016. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27274814",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Background Data from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several patients with Ebola virus disease (EVD) managed in the United States have received ZMapp monoclonal antibodies, TKM-Ebola small interfering RNA, brincidofovir, and/or convalescent plasma as investigational therapeutics.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27521366",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Also there is no specific vaccine and treatment for Ebola virus; however, many candidate vaccines and antiviral-drugs such as ZMapp and TKM-Ebola are being developed for Ebola virus disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648530",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Going forward, this work now provides a basis for strategic selection of next-generation antibody cocktails against Ebola and related viruses and a model for predicting the impact of ZMapp on potential escape mutations in ongoing or future Ebola outbreaks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404321",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Some potential therapeutic materials including ZMapp were supplied and the treated people got over the EVD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648233",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cocktails of inhibitory monoclonal antibodies (MAbs), such as ZMAb, MB-003, and in particular ZMapp, have demonstrated in animal models some of the most significant therapeutic potential for treating EVD, and in 2014, 15 patients were treated with ZMapp or ZMAb under compassionate-use protocols.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This review explores some of the more prominent recent advances in the biofarming of viral vaccines and therapies, including the recent use of ZMapp for Ebolavirus infection, and explores some possible future applications of the technology.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25465382",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cocktails of inhibitory monoclonal antibodies (MAbs), such as ZMAb, MB-003, and in particular ZMapp, have demonstrated in animal models some of the most significant therapeutic potential for treating EVD, and in 2014, 15 patients were treated with ZMapp or ZMAb under compassionate-use protocols.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For example, several patients of the present Ebola virus outbreak in West Africa were treated with ZMapp, a cocktail of three monoclonal antibodies which are expressed in Nicotiana benthamiana.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26191408",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:4",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"
  ],
  "exact_answer": "Ebola virus disease, Ebola virus infection"
}